Promising efficacy of SHR‐1210, a novel anti–programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China-Reference-Cited by-同舟云学术

Promising efficacy of SHR‐1210, a novel anti–programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China

Published:2018-12-03 Issue:5 Volume:125 Page:742-749
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Huang Jing¹^ORCID,Mo Hongnan¹,Zhang Weilong²,Chen Xuelian¹^ORCID,Qu Dong³,Wang Xi¹,Wu Dawei¹,Wang Xingyuan¹,Lan Bo¹,Yang Beibei²,Wang Pei²,Zhang Bo¹,Yang Qing⁴,Jiao Yuchen²,Xu Binghe¹

Affiliation:

1. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Department of Diagnostic Radiology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

4. Jiangsu Hengrui Medicine Co., Ltd Shanghai China

Funder

Chinese Academy of Medical Sciences

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31855

Reference18 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Cancer statistics in China, 2015